Oramed Pharmaceuticals (ORMP) Interest Expenses (2011 - 2024)

Oramed Pharmaceuticals (ORMP) reported Interest Expenses of $261000.0 for Q2 2024, down 55.91% quarter-over-quarter from $592000.0 in Q1 2024.

Oramed Pharmaceuticals (ORMP) Interest Expenses (2011 - 2024) Analysis & Trends

Oramed Pharmaceuticals has reported Interest Expenses for 11 years, with the latest figure at $261000.0 in Q2 2024.

For the quarter ending Q2 2024, Interest Expenses changed N/A year-over-year to $261000.0; the trailing twelve-month figure through Mar 2025 stood at $261000.0 (down 90.07% YoY), and the FY2024 full-year result was $853000.0, down 58.12% from the prior year.
Interest Expenses for Q2 2024 stood at $261000.0, down from $592000.0 in the prior quarter.
The five-year high for Interest Expenses was $1.2 million in Q4 2023, with the low at $261000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-5.50 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	61,000.00
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-332,000.00
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-5.58 Mn
10	Oramed Pharmaceuticals	151.47 Mn	133.31 Mn	-	-

Download Data